450 EAST 29TH STREET, NEW YORK, NY
Market cap: $646.3M (12/18/2025)
Price: $8.03
Reports Third Quarter 2025 Financial and Operational Results
Enters into Strategic Collaboration to Develop and Commercialize Genetic Medicines in Ophthalmology
Reports Second Quarter 2025 Financial and Operational Results
Reg. FD
Shareholder votes
Reports First Quarter 2025 Financial and Operational Results
Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
Annual Report to Security Holders
Q3
Q2
Q1
FY 2024
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Correspondence
Submission Upload